RXST
T3RxSight, Inc.
OverviewRxSight, Inc. (RXST) is a medical technology company specializing in Light Adjustable Lenses (LALs) for cataract surgery. Its RxSight system, including an in-of
RxSight, Inc. (RXST) is a medical technology company specializing in Light Adjustable Lenses (LALs) for cataract surgery. Its RxSight system, including an in-office light delivery device, enables eye surgeons to precisely customize a patient's vision post-surgery. LAL sales represent the vast majority of product revenue, with a new strategic collaboration with Alcon contributing additional revenue. RxSight primarily sells to eye surgeons globally.
- What They Do (Plain English & Analogies)
- RxSight, Inc. makes special artificial lenses for cataract surgery called Light Adjustable Lenses (LALs). Unlike traditional lenses that are fixed once implanted, these LALs can be fine-tuned *after* they've been placed in a patient's eye. Imagine getting a new pair of glasses, but instead of being stuck with the prescription, you can go back to the eye doctor a few times to adjust the lenses until your vision is perfect. RxSight provides both the LAL and a special light machine, called a Light Delivery Device (LDD), which the eye doctor uses in their office to make these adjustments with UV light. This allows for very precise vision correction, customized to each patient's actual healing and visual needs, rather than relying solely on pre-surgery estimates. The company is dedicated to improving people's vision by offering this unique ability to personalize visual outcomes post-surgery.
- Very Brief History
- RxSight, Inc. was founded in 1997, initially operating as Calhoun Vision, Inc., before rebranding in February 2017. The company focused on developing light-adjustable intraocular lens technology to address the challenge of precisely adjusting vision after IOL implantation in cataract surgery. Key milestones include the first U.S. clinical trial of the Light Adjustable Lens (LAL) in 2014, followed by FDA approval of the LAL and Light Delivery Device (LDD) in 2017. RxSight commercially launched its system in the U.S. in 2019, went public on NASDAQ in 2021, and began expanding into international markets in 2022. New LAL models with enhanced features were introduced in 2023.
- "Street Stereotype"
- The "street stereotype" for RxSight is that of an innovative, niche medical technology company with a groundbreaking, differentiated product (the Light Adjustable Lens) in the premium cataract surgery market. However, it faces challenges in broader commercial adoption and consistent growth, leading to a "Hold" consensus rating from analysts. Investors are focused on whether the company can successfully re-engage customers, accelerate LAL utilization, and achieve sustainable long-term growth and profitability, especially given its current unprofitability and high operating expenses. There's cautious optimism about its technology but also concerns about execution and competition.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- RxSight's customers are primarily in the **ophthalmic medical sector**, specifically **eye surgeons and ophthalmology practices** specializing in cataract treatments and refractive surgery. The company sells its Light Delivery Devices (LDDs) and Light Adjustable Lenses (LALs) directly to these practices. While specific client names are not provided, these would be individual ophthalmology clinics, eye surgery centers, and larger hospital systems with ophthalmology departments that perform cataract surgery.
- New Customers / Segments They'Re Targeting
- RxSight is targeting a broader array of patients by expanding the offering of adjustability across a wider range of lenses, particularly through its collaboration with Alcon to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This collaboration aims to bring the power of adjustability to as many cataract patients as possible, including those seeking spectacle independence after surgery. The company also plans to double its U.S. sales team over time to expand its reach and support existing customers, aiming to drive higher utilization across its installed base.
- Supply Chain And Sourcing Geographies
- RxSight has intentionally pursued a vertically integrated manufacturing strategy, which they believe offers advantages in product quality control and rapid product iteration. Their headquarters and manufacturing facilities are located in Aliso Viejo, California, where they have expanded their footprint to include R&D, manufacturing, industrial, and office uses across four facilities. The company's annual report in 2022 indicated that they control critical components and engage in second sourcing, but also acknowledge the risk of supply interruptions from suppliers. The transcript does not provide further specific details on sourcing geographies for components.
- Sales Geographies And Expansion Plans
- RxSight currently sells its products in the **United States** and select **international markets**. Current international markets where they have received approvals and are gaining traction include Asia (Korea, Singapore), Europe, Australia, and New Zealand. The company has plans for continued international expansion, with a focus on establishing optimal clinical, commercial, and operational infrastructure in each market. They are working through regulatory processes in countries with longer cycles, such as Japan, China, and India. While international contributions are expected to be modest in the near term (2026), they anticipate becoming a more meaningful driver of growth in 2027 and beyond.
- How Key Themes May Help/Hurt
- The primary focus theme, "MedTech Long '25: Wearable Health," has no direct relevance to RxSight's business model. RxSight specializes in intraocular lenses for cataract surgery, which does not involve wearable or sensor-based platforms for chronic disease monitoring, mobility restoration, or cardiac/diabetes management. Therefore, RxSight is neither directly benefited nor hurt by the buildout of this specific theme.
3 Main Long-Term Bull Details
- Unique and Differentiated Technology: The Light Adjustable Lens (LAL) is the only FDA-approved intraocular lens that allows for post-operative customization of vision, offering superior precision and patient outcomes compared to traditional fixed IOLs. This unique adjustability addresses a critical need for enhanced accuracy and patient satisfaction in cataract surgery.
- Significant Market Opportunity and Expansion: The premium IOL market is projected to grow significantly, potentially from 15-20% to 30-40% of the overall cataract market. The LAL's broad applicability, flexibility, and appeal to patients seeking control over their vision position RxSight to capture a substantial share of this growing market, both in the U.S. and through measured international expansion into key regions like Europe, Asia, and Australia.
- Strategic Collaboration with Alcon: The non-exclusive collaboration with Alcon, a leader in the eye care industry, provides significant external validation of RxSight's technology and its broader potential. This partnership includes $200 million in upfront and potential future milestone payments, along with the potential for significant long-term royalties, and aims to expand the offering of adjustability across a wider range of lenses, including presbyopia-correcting IOLs, to a broader patient base.
3 Main Long-Term Bear Details
- Challenges in Commercial Adoption and Utilization: Despite the differentiated technology, RxSight faces ongoing challenges in driving consistent LAL procedure volume and utilization, as evidenced by the 9% year-over-year decline in LAL unit volumes in Q2 2026 and a 19% decline in product sales. The company is working to strengthen its commercial strategy and execution, including doubling its U.S. sales team, but this will take time to translate into broader adoption.
- Competitive Headwinds and Market Conditions: The company expects continued competitive activity from "Me-Too Fixed IOLs" and ongoing product trialing, along with broader marketplace headwinds and seasonality, to influence performance. While RxSight believes its technology is superior, new product introductions by larger competitors can create transient impacts on market share.
- Uncertainty from Guidance Withdrawal and Path to Profitability: RxSight withdrew its full-year 2026 financial guidance to allow the new CEO to complete a thorough assessment of the business. This decision, made recently after guidance was initially provided, signals potential for significant strategic changes and creates near-term uncertainty for investors regarding future financial performance and the company's path to consistent profitability, given its current net losses and high operating expenses.
- Competitors And Differentiation
- RxSight's primary differentiation lies in its Light Adjustable Lens (LAL) technology, which is the only FDA-approved intraocular lens that allows for post-operative customization of vision. This unique adjustability enables surgeons to fine-tune visual outcomes after cataract surgery, offering superior precision and patient satisfaction compared to traditional fixed IOLs. Competitors in the premium IOL market include established players like Alcon, Johnson & Johnson, Bausch + Lomb, Zeiss, and Rayner, who offer various "Me-Too Fixed IOLs" and other advanced lenses such as extended depth of focus (EDOF) and multifocal IOLs. While new premium IOLs are continuously introduced, RxSight believes its adjustability offers a superior clinical outcome.
- Recent Performance & What The Market'S Focused On
- RxSight's second quarter 2026 total company revenue was $33.7 million, including $6.5 million from its strategic collaboration agreement with Alcon. Excluding the Alcon revenue, product sales were $27.2 million, down 19% compared to the prior year. LAL unit volumes were 24,917, a 9% decrease year-over-year, and LDD placements were 12 units. The company reported a net loss of $12.1 million. Management has withdrawn its previously issued full-year 2026 financial guidance to complete a thorough assessment of the business, with plans to resume formal guidance in early 2027. The market is focused on the new CEO's assessment and strategic direction, the ability to drive higher LAL utilization, the impact of competitive launches and market conditions, and the revenue contribution and progress of the Alcon collaboration.
- Revenue Segments And Estimated Mix
- Light Adjustable Lens (LAL) sales — Mix: ~72.7%; Source: Q2 2026 earnings transcript; Trend: Q2 2026 sales were $24.5 million; unit volumes down 9% year-over-year
- Alcon Strategic Collaboration Revenue — Mix: ~19.3%; Source: Q2 2026 earnings transcript; Trend: Q2 2026 revenue was $6.5 million
- Light Delivery Device (LDD) sales — Mix: ~3.9%; Source: Q2 2026 earnings transcript; Trend: Q2 2026 sales were $1.3 million from 12 units placed
- Other Product Sales — Mix: ~4.2%; Source: Calculated from Q2 2026 earnings transcript (Total Product Sales - LAL Sales - LDD Sales)
- Product Brands
- Light Adjustable Lens
- LAL
- RxSight system
- RxSight light delivery device
- LDD
- LAL+
Bull / Bear DetailsRxSight, Inc. (RXST) is a medical technology company poised for long-term growth, leveraging its differentiated Light Adjustable Lens (LAL) system for superior,
Thesis
RxSight, Inc. (RXST) is a medical technology company poised for long-term growth, leveraging its differentiated Light Adjustable Lens (LAL) system for superior, customizable post-cataract vision correction. Despite recent LAL volume declines and near-term uncertainty from a strategic business assessment and withdrawn guidance, the new CEO's focus on commercial execution, sales team expansion, and the validating Alcon collaboration are expected to drive renewed LAL utilization and market share gains in the expanding premium IOL segment. (Updated: 2026-08-06)
Bull case
The strategic collaboration with Alcon is a major milestone, providing significant external validation for RxSight's technology and reinforcing the belief that adjustability is the future of cataract surgery. This partnership offers meaningful non-dilutive capital through upfront payments and potential future milestones, along with long-term royalties, which will support the company's growth initiatives and expand the reach of adjustability across a wider range of lenses.
Physician confidence in the LAL system remains exceptionally high, with the new CEO noting that surgeons prefer LAL for their most important patients, including family members. This strong belief in the technology's differentiation and its ability to deliver precise, personalized vision is supported by extensive clinical and real-world evidence, indicating a solid foundation for driving deeper utilization.
The new CEO's immediate priority to complete a thorough business assessment and strengthen commercial execution includes plans to double the U.S. sales team over time. This expansion, funded by reallocating resources, aims to enhance customer support, improve workflow integration, and drive higher procedure volume and utilization within the existing installed base, addressing a key challenge for the company.
Bear case
RxSight has withdrawn its full-year 2026 financial guidance to allow the new CEO to complete a thorough business assessment and ensure flexibility for potential strategic decisions. This withdrawal, despite encouraging quarter-to-date trends, introduces significant near-term uncertainty regarding the company's financial performance and strategic direction until formal guidance resumes in early 2027.
The company reported a 19% year-over-year decline in Q2 2026 product sales and a 9% year-over-year decrease in LAL unit volumes, alongside only 12 LDD placements. These figures reflect persistent challenges in driving broader adoption and utilization of the LAL platform, indicating that competitive trialing, market headwinds, and patient affordability continue to impact core business performance.
Despite the revenue contribution from the Alcon collaboration, RxSight reported a net loss of $12.1 million in Q2 2026. The core product gross margin, excluding the Alcon benefit, also declined to 71.2% from 74.9% in the prior year, primarily due to higher inventory-related costs. This highlights ongoing profitability challenges and cost pressures amidst increased investments in the commercial organization.
Bull / Bear Case
- Bear Case
- RxSight faces significant near-term uncertainty due to the withdrawal of its full-year 2026 financial guidance, allowing the new CEO to complete a business assessment. This decision, despite some encouraging quarter-to-date trends, signals potential strategic shifts and leaves investors without a clear financial outlook until early 2027. The core business performance shows concerning declines, with Q2 2026 product sales down 19% year-over-year and LAL unit volumes decreasing 9% year-over-year, alongside only 12 LDD placements. The company continues to report net losses ($12.1 million in Q2 2026) and declining core product gross margins, indicating ongoing profitability challenges and cost pressures. Competitive activity, market headwinds, and patient affordability issues are expected to persist, further impacting performance and posing execution risks to the new commercial strategy.
- Bull Case
- RxSight's Light Adjustable Lens (LAL) system represents a highly differentiated and unique technology in cataract surgery, offering superior post-operative vision customization that physicians highly value, even for their own families. This strong clinical proposition is supported by extensive evidence and positions RxSight favorably in the expanding premium IOL market, which is projected to grow significantly. The strategic collaboration with Alcon provides substantial external validation, non-dilutive capital through upfront and milestone payments, and long-term royalties, reinforcing the belief that adjustability is the future of cataract surgery. Furthermore, the new CEO, Aziz Mottiwala, is prioritizing a thorough business assessment and plans to double the U.S. sales team to drive deeper utilization within the existing installed base, funded by reallocating resources without significantly increasing overall operating expenses, with encouraging quarter-to-date trends noted.
- More Compelling & Why
- Bear. The company's current unprofitability, reflected in negative P/E and EV/EBITDA ratios, and a P/S ratio of approximately 2x which is considered expensive relative to some peers, makes the bear case more compelling. The withdrawal of full-year 2026 guidance, coupled with significant year-over-year declines in core product sales and LAL unit volumes, highlights fundamental business challenges. My view would flip to bullish upon RxSight demonstrating sustained sequential and year-over-year positive growth in LAL unit volumes and providing clear 2027 guidance that outlines a credible path to profitability.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Light Delivery Device (LDD) Unit Sales and Expansion of Rental Program | LDD placements are crucial for expanding RxSight's installed base, which directly enables future recurring LAL sales. The new rental option could lower barriers to entry and accelerate adoption, especially in international markets. | Sequential improvement in LDD unit sales in Q3 and Q4 2026 from Q2's 12 units. Watch for commentary on the success and expansion of the LDD rental program, particularly in international markets. | Bullish if LDD unit sales show sequential growth and if the rental program demonstrates strong uptake, indicating increased interest from new practices and successful market penetration. Bearish if LDD unit sales stagnate or decline, or if the rental program fails to gain traction. | Company earnings reports and conference calls (Q3 2026 earnings call, likely November 2026). | Bloomberg Supply Chain: Tracking LDD shipments (if available for medical devices). | |
| Progress on New Commercial Strategy and U.S. Sales Team Expansion | The new CEO's immediate priority is a thorough business assessment and strengthening the commercial team, including doubling the U.S. sales force. This is a direct effort to improve LAL utilization and drive core business growth. | Commentary from management on the progress of the business assessment, hiring for the expanded U.S. sales team, and early indicators of improved LAL utilization from existing accounts. | Bullish if management reports significant progress in the business assessment, successful hiring for the sales team expansion, and early positive impacts on LAL utilization rates. Bearish if there are delays in implementing the new strategy or if utilization rates do not show improvement. | Company earnings reports and conference calls (Q3 2026 earnings call, likely November 2026; Q4 2026 earnings call, early 2027). | LinkedIn: RxSight job postings for U.S. sales roles. | Thinknum: RxSight sales job postings 30-day growth. |
| Resumption of Formal Full-Year Financial Guidance for 2027 | The withdrawal of 2026 guidance created uncertainty. The resumption of formal guidance in early 2027 will provide investors with clarity on the company's strategic direction, growth expectations, and confidence under the new CEO. | The announcement of formal full-year 2027 financial guidance, including revenue, LAL unit volumes, and gross margin expectations. This is expected when the company reports its Q4 2026 results. | Bullish if the 2027 guidance reflects a clear growth trajectory, improved profitability outlook, and confidence in the new commercial strategy. Bearish if the guidance is conservative, indicates continued headwinds, or is further delayed. | Company earnings reports and conference calls (Q4 2026 earnings call, expected early 2027). | ||
| Alcon Strategic Collaboration Revenue Recognition and Achievement of Development Milestones | The Alcon collaboration provides significant non-dilutive capital and external validation of RxSight's technology, crucial for funding future growth and expanding the market for adjustable IOLs. | Actual collaboration revenue recognized in Q3 and Q4 2026. Management anticipates limited revenue contribution in Q3 and the balance of the $30 million to $40 million full-year guidance recognized in Q4 2026. Also, watch for updates on achieving development milestones for next-generation products. | Bullish if collaboration revenue meets or exceeds the $30M-$40M full-year guidance and if positive progress on new product development milestones is announced. Bearish if collaboration revenue falls short or if there are delays in product development. | Company earnings reports and conference calls (Q3 2026 earnings call, likely November 2026; Q4 2026 earnings call, early 2027). | Company press releases regarding Alcon partnership updates. | |
| Light Adjustable Lens (LAL) Unit Volume Growth (Standalone) | LAL unit volumes are the primary driver of RxSight's core product revenue. Sustained growth indicates successful customer re-engagement and market penetration, validating the long-term investment thesis. | Sequential and year-over-year LAL unit sales in Q3 and Q4 2026. Q2 2026 LAL unit sales were 24,917, down 9% year-over-year. Watch for Q3 2026 LAL unit volumes to show sequential improvement and a reduced year-over-year decline, ideally moving towards positive growth. | Bullish if LAL unit sales show sequential improvement from Q2's 24,917 units and a reduced year-over-year decline in Q3 2026, indicating successful re-engagement efforts. Bearish if LAL unit sales continue to decline year-over-year or sequentially. | Company earnings reports and conference calls (Q3 2026 earnings call, likely November 2026). | Google Trends: 'RxSight Light Adjustable Lens' search volume. | IQVIA DeviceTrack: LAL unit shipments to ophthalmology practices. |
Key Reported Metrics, Reratings Triggers & ResultsGross margin is a key indicator of profitability and operational efficiency. Management anticipated a step-down from Q1 due to higher cost inventory, making its
Upcoming print · 2026-11-04
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Gross Margin | 1.7% | Gross margin is a key indicator of profitability and operational efficiency. Management anticipated a step-down from Q1 due to higher cost inventory, making its trend important for investor confidence and future earnings. |
| LAL Unit Volumes | -10% | LAL unit volumes are crucial as they represent the adoption and utilization of RxSight's primary product. This metric directly impacts revenue and reflects the success of commercial strategies and customer reengagement efforts. |
| Total Revenue (excluding Alcon collaboration) | -20% | This metric will show the underlying performance of RxSight's core business, separate from the new Alcon collaboration, indicating the effectiveness of reengagement programs and market demand for its primary products. |
Last reported · 2026-08-05
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Total Product Sales (excluding Alcon collaboration) | -19% | This metric indicates the underlying performance of RxSight's core business, separate from the new Alcon partnership. It will show whether re-engagement programs are effectively reversing recent declines and managing competitive headwinds. | ||||||
| Alcon Collaboration Revenue | N/A | This new revenue stream from the strategic collaboration with Alcon is crucial for validating RxSight's technology and providing non-dilutive capital. Meeting the anticipated Q4 revenue recognition is key for investor confidence. | ||||||
| LAL Unit Volumes | 24,917 units (-9% y/y growth) | This metric directly reflects the adoption and utilization of RxSight's core product. Sequential improvement and reduced year-over-year decline will indicate the success of the new CEO's commercial strategy and re-engagement efforts. | Light Adjustable Lens (LAL) Unit Sales Growth of at least 3% year-over-year for Q2 2026, significantly outperforming the preliminary 10% year-over-year decline. This would equate to reporting at least 28,500 LAL units sold for the quarter. | Hitting this threshold is crucial as LAL unit sales are RxSight's core revenue driver. Positive, accelerating growth validates re-engagement efforts and market penetration, signaling a clear path to sustainable long-term growth and improved profitability. This would justify a higher valuation and strengthen the investment thesis. | 24,917 units (-9% y/y growth) | No | LAL unit volumes declined by 9% year-over-year, falling short of the 3% year-over-year growth target of at least 28,500 units. This indicates continued challenges in driving adoption, despite the new CEO's focus on strengthening the commercial team and improving utilization. | |
Key QuestionsCan the new CEO's strategic assessment and planned commercial model changes, including doubling the U.S. sales team, effectively reverse the year-over-year decl
Can the new CEO's strategic assessment and planned commercial model changes, including doubling the U.S. sales team, effectively reverse the year-over-year decline in LAL unit volumes and drive increased utilization in the coming quarters, setting a clear path for renewed growth in 2027?
- Question 2
Will RxSight successfully achieve the anticipated $30 million to $40 million in revenue from the Alcon strategic collaboration in 2026, particularly with the majority expected in Q4, and demonstrate clear progress on development milestones for next-generation products, validating its long-term strategic value?
- Question 3
Can RxSight improve its core business gross margin from Q2's 71.2% and, through strategic reallocation of resources to double its U.S. sales team without meaningfully increasing overall operating expenses, demonstrate a clear path to sustainable operating leverage and profitability?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Completing a thorough assessment of the business and commercial model**: The new CEO, Aziz Mottiwala, stated this as his immediate priority to understand underlying challenges and identify areas for greatest impact, ensuring flexibility for long-term strategic decisions. 2. **Strengthening the commercial team and building higher utilization**: Management plans to double the U.S. sales team over time to expand reach and support existing customers, aiming to increase procedure volume and utilization of the LAL platform. 3. **Elevating execution and operating discipline**: This includes improving forecasting through greater visibility into business drivers and enhancing agility to adapt quickly to marketplace changes. | The call conveyed a cautious but determined tone, marked by the introduction of a new CEO, Aziz Mottiwala. He acknowledged the challenges reflected in the Q2 results, with product sales down 19% year-over-year and LAL volumes down 9% year-over-year. The key takeaway is a strategic reassessment under new leadership, leading to the withdrawal of full-year guidance to allow flexibility for potential changes. Management is focused on improving commercial strategy, strengthening the sales team (doubling it over time), and enhancing operational discipline to drive deeper utilization of the LAL platform. Despite the near-term headwinds and strategic pause, there's underlying confidence in the differentiated technology and its long-term potential, supported by strong physician belief and the validation from the Alcon collaboration. | In Q1 2026, total sales declined 18% year-over-year. LAL revenue decreased 1% year-over-year, and LAL unit volumes were in line with the year-ago period (approximately 0% year-over-year growth). LDD revenue decreased 72% year-over-year. | 1. **Deceleration in growth and lower utilization, and how to address it**: Analysts questioned the reasons for the slowdown. Management (Aziz Mottiwala) attributed it to a pivot from establishing a broad user base to driving 'depth' of utilization. He emphasized that doctors still believe in the technology and want to use more LALs, and the focus will be on improving workflow, identifying ideal patients, and enhancing education. 2. **Withdrawal of full-year financial guidance**: Analysts asked if this suggested bigger changes. Management (Aziz Mottiwala) clarified it was to allow flexibility for a thorough assessment and potential acute changes to orient the business for long-term growth, not a signal about current business performance. They expect to resume formal guidance in early 2027. 3. **Impact of the Alcon collaboration on standalone OUS commercial strategy and potential for other non-exclusive deals**: Analysts inquired if the Alcon deal altered OUS strategy and if similar agreements could be envisioned. Management (Aziz Mottiwala) stated that the OUS strategy is separate and thoughtful, focusing on markets with real potential. Regarding other deals, while the Alcon collaboration is not exclusive, the current focus is on maximizing the value of the existing partnership. | Second quarter total company revenue was $33.7 million, including $6.5 million recognized from the strategic collaboration agreement with Alcon. Excluding revenue related to Alcon, product sales were $27.2 million, down 19% compared to the prior year period. LAL unit volumes were 24,917, down 9% compared to the prior year period. LDD units placed were 12, which accounted for $1.3 million of quarterly revenue. |
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Refining and accelerating customer reengagement programs**: Management is encouraged by the progress of these programs, which include clinical outcome reviews, targeted IOL counseling training, refresher education, and in-person workflow support, aiming to drive utilization and confidence in LAL technology. 2. **Measured and thoughtful international expansion**: The goal is to build a durable foundation for long-term growth outside the U.S. by establishing optimal clinical, commercial, and operational infrastructure and building relationships with leading surgeons. 3. **Strengthening the team, improving execution, and driving technical innovations**: This includes planned commercial introductions to simplify LAL implementation, reduce adoption friction, streamline clinical workup for adjustments, reduce required LDD treatments, and extend the range of correction. | The call conveyed a cautiously optimistic tone. RxSight is focused on stabilizing its core U.S. LAL business through targeted customer reengagement programs, which are showing early positive signs. The company is also pursuing a deliberate international expansion and investing in R&D for future product innovations to simplify LAL use and expand its applicability. While Q1 saw an overall revenue decline, LAL volumes were stable year-over-year, and management expects sequential improvement throughout 2026. Management expressed confidence in their strategies and the long-term value proposition of LAL, acknowledging that there is 'still work to do' but seeing 'clear early signs' of progress. | In Q4 2025, total revenue decreased 19% year-over-year. LAL revenue decreased 1% year-over-year, while LDD revenue decreased 72% year-over-year. | 1. **Turnaround efforts, Q2 green shoots, and 2027+ growth**: Analysts questioned the effectiveness of reengagement programs and the company's ability to return to material growth. Management responded that feedback on reengagement programs is positive, and they are confident in continued refinement and expansion. They expect growth rates to improve throughout 2026 due to improving fundamentals and easing comparisons, and they are investing for long-term sustainable growth in 2027 and beyond through technological innovation and international expansion. 2. **LAL adoption stabilization drivers and LDD sales strategy**: Analysts asked if LAL stabilization was due to market conditions or company efforts, and if LDD sales were being restricted. Management stated that their actions are having a positive impact, though it's hard to fully parse out market factors. They clarified they are not 'gating' LDD sales but taking a more measured approach to ensure customer success and readiness for adoption. 3. **Impact of increasing competition and international expansion details**: Analysts inquired about new premium IOL competitors and requested more specific financial details on international contributions. Management believes LAL's clinical outcomes are superior to new, undifferentiated products, though transient impacts are possible. Regarding international, they noted early traction in Asia, Europe, and Australia/New Zealand, but stated contributions remain modest and not yet material enough to break out specific dollar amounts. | Total sales declined 18% year-over-year to $30.9 million. LDD unit volumes experienced a year-over-year step down, with 20 LDDs sold accounting for approximately $2 million in sales. LAL unit volumes of 27,472 were in line with the year-ago period, translating to approximately $27 million in sales, representing 88% of total company sales. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| RxSight's collaboration with Alcon is seen as a major milestone, providing external validation and reinforcing the belief that adjustability is the future of cataract surgery. This partnership is expected to expand the offering of adjustability across a wider range of lenses, reaching a broader array of patients, with the vision of a world where every premium lens has the value of adjustability. The company is also pursuing international expansion, having received recent regulatory approvals in markets like New Zealand and continuing commercial efforts in Europe and Asia. They aim to be thoughtful about entering markets with real potential and are working through regulatory processes in countries with longer cycles such as Japan, China, and India. | The company noted heightened competitive trialing and broader marketplace headwinds in the second quarter. Competitive launches, market conditions, seasonality, and patient affordability were cited as factors affecting quarterly performance. While the collaboration with Alcon is not exclusive, RxSight's current focus is on maximizing the value of this partnership with a leader in the industry. The company acknowledges that competitive activity and ongoing product trialing are expected to influence performance through the remainder of the year. | The eye care sector represents a significant opportunity to make life-changing differences in patients' lives. A key trend is that patients are becoming increasingly demanding, expecting physicians to deliver real results and perfect vision, moving beyond 'good enough.' The demographic of cataract surgery patients is changing, with people living more active lifestyles and desiring to maintain their younger-year capabilities. This leads to a higher premium on technologies and products, both pharmaceutical and device-related, that offer truly meaningful outcomes and meet the increasing satisfaction expectations of patients. | RxSight has withdrawn its full-year financial guidance for 2026 to allow for a thorough business assessment and ensure flexibility for potential strategic decisions, with formal guidance expected to resume in early 2027. The company anticipates recognizing $30 million to $40 million in revenue from the Alcon strategic agreement in 2026, with limited contribution in Q3 and the balance in Q4. Immediate priorities include completing a thorough assessment of the business and commercial model, strengthening the commercial team to drive higher utilization across the installed base, and planning to double the U.S. sales team over time by reallocating resources without meaningfully increasing overall operating expenses. The company also aims to elevate execution and operating discipline, including improved forecasting and agility, and continue advancing its internal pipeline of next-generation adjustable lenses. They will focus on achieving development milestones with Alcon to advance next-generation products to commercialization, expecting meaningful long-term value through future royalties. | A broader theme emerging is the increasing demand for personalized and perfect outcomes in healthcare, particularly in elective procedures like cataract surgery, driven by changing patient demographics and higher expectations for quality of life post-treatment. This trend places a higher value on differentiated technologies that can consistently deliver superior and customized results. Additionally, there's an emphasis on operational discipline, strong customer engagement, and continuous education within the medical technology sector to drive adoption and utilization of innovative solutions. | The value of adjustability remains compelling and that physicians recognize the technology's differentiation. Most surgeons prefer LAL for their most important patients, including members of their own family. Our recently announced collaboration with Alcon is a major milestone for the company. This collaboration reinforces our belief that adjustability is the future of cataract surgery. We are encouraged by quarter-to-date trends, particularly the continued confidence physicians have expressed in our technology. I really believe that this has tremendous potential and that we've just scratched the surface. Doctors continue to believe that this is one of the best technologies. There's not a significant major obstacle to opening this up. | We have considerable work ahead of us to translate this opportunity into broader adoption. For that reason, we have decided to withdraw our previously issued full-year financial guidance. Second quarter product sales were $27.2 million, down 19% compared to the prior year period, reflecting heightened competitive trialing as well as broader marketplace headwinds. Second quarter LAL unit volumes were 24,917, down 9% compared to the prior year period. We reported a net loss in the second quarter of $12.1 million. We expect continued competitive activity and ongoing product trialing, along with typical Q3 seasonality and broader market trends to influence performance through the remainder of the year. Our second quarter results underscore the work we have ahead of us. We are not yet driving the level of procedure volume and utilization that we believe this platform is capable of achieving. | RxSight has approved plans to double its U.S. sales team over time to expand reach and support existing customers, intending to fund this expansion by reallocating resources within the organization without meaningfully increasing overall operating expenses. Conversely, research and development expenses saw a year-over-year decline primarily due to lower personnel-related expenses. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| RxSight is taking a measured and thoughtful approach to international expansion to build a durable foundation for long-term growth outside the U.S., with the opportunity becoming a more meaningful driver of growth in 2027 and beyond. The company recently received approval in New Zealand, expanding the global reach of the LAL system. Efforts are gaining traction in Asia (Korea, Singapore), Europe, Australia, and New Zealand, mirroring where the premium IOL business has seen success. RxSight is also working through regulatory processes in countries with longer cycles like Japan, China, and India. | Despite the introduction of numerous 'Me-Too Fixed IOLs,' RxSight maintains its conviction that adjustability represents the next meaningful step forward, believing the clinical outcomes achievable with adjustability are superior. While new premium IOLs like TECNIS PureSee from J&J, a BVI product, and a Rayner product are coming to market, RxSight believes there's 'not a lot new under the sun' fundamentally. The company acknowledges that multiple players can create transient impacts but feels strongly that its technology will ultimately prevail. Regarding adjustable competition, RxSight is not aware of anything close to a regulatory process, especially in the U.S., highlighting the high bar and its established installed base and knowledge in the community. | The broader cataract market, particularly the non-premium segment, has seen some softness, possibly due to macro factors affecting patients' ability to pay co-pays. However, the premium segment of the market continues to show growth both in the U.S. and internationally. A large competitor projected that the premium market could grow from the current 15-20% to potentially 30-40%, driven by technologies like the LAL which offer broad applicability, flexibility, and appeal to patients seeking control and input in their vision correction process. | RxSight plans to continue refining and accelerating customer reengagement programs launched in the second half of 2025 throughout 2026 and beyond. The company reiterates its full-year 2026 revenue guidance of $120 million to $135 million, expecting quarterly sales growth rates to improve throughout the year. International business is anticipated to be a modest contributor in 2026, primarily from early capital placements. Operating expenses are forecasted at the high end of the $150 million to $160 million range for 2026, reflecting accelerated investments in the global commercial organization. The business appears to be stabilizing, and RxSight is focusing on strengthening its team, improving execution, and driving technical innovations to simplify LAL implementation, streamline clinical workup, reduce required LDD treatments, and extend the range of correction, with details on commercialization to be shared as regulatory processes progress. | Wearable | Broader themes emerging include the significant growth and importance of the premium segment in ophthalmology, the increasing demand for personalized medicine and patient empowerment in healthcare decisions, and the ongoing focus within MedTech on workflow optimization and simplification of complex medical procedures through technological innovation and enhanced customer support. | LAL volumes were consistent with prior year levels and utilization has now stabilized for the third consecutive quarter. More importantly, we're starting to see clear early signs that these efforts are working. The core clinical value proposition of LAL remains strong and clearly differentiated in the premium IOL market. The business appears to be stabilizing and our customer engagement programs are beginning to show initial progress. We think of ourselves as a growth company. We invest for long-term sustainable growth, and that includes 2027 and beyond. The premium market is incredibly important to ophthalmology... and they projected that their view is that, that premium market is going to go from the current 15% to 20%, depending on geography to maybe the 30% to 40%. | Q1 sales of $30.9 million declined 18%, reflecting a year-over-year step down in LDD unit volumes consistent with expectations. Q1 LAL unit volumes of 27,472 were in line with the year ago period and down 4% sequentially. While we expect international contributions to remain modest in the near term. Anticipated step down from Q1 gross margin reflects the flow-through of higher cost inventory manufactured in 2025. There can be, as there have been with past introductions, some transient impact from these efforts and the overall impact they have on other competitors as well. A competitor just reported recently and noted softness in the cataract market. | First quarter 2026 SG&A expenses were up 11% compared to the prior year, driven by personnel-related expenses as RxSight continues to prioritize investments in new hires and ongoing expansion of its global commercial and support teams. The company is forecasting 2026 operating expenses at the high end of its previous range, reflecting accelerated investments in its global commercial organization. RxSight currently has about 130 to 150 field-facing employees, which has grown with its installed base and recent initiatives, and decisions on additional spending will be based on the success of these initiatives and other business priorities. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-05-06 | RxSight's Q1 2026 earnings revealed an 18% revenue decline and a wider net loss, despite LAL volume stabilization and reiterated full-year guidance. Management emphasized reengagement program progress and international expansion. However, the market reacted negatively, with the stock dropping nearly 20% (t+2 days), contradicting the company's messaging and indicating investor concerns over revenue pressure and increased operating expenses. | Earnings Transcript | Mixed | -19.42% (vs SPY: -21.33%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| RXST_99260578 | early 2027 | 2027-01-01 | 2027-03-31 | Resumption of formal full-year financial guidance. | This will provide investors with clarity on management's expectations for the company's performance after the business assessment, impacting investor confidence and valuation. | Ticker | 2026-08-05 | earnings_transcript |